Tocilizumab, Drugs Monitor, Page 7

(24 July 2020) Tocilizumab- associated with low mortality, and no major safety concerns in severe COVID-19 pneumonia

July 25, 2020

Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study https://doi.org/10.1016/j.jaut.2020.102523 The objective of this work was to describe the clinical characteristics and predictors of major outcomes in patients treated with tocilizumab (TCZ) for… Continue reading "(24 July 2020) Tocilizumab- associated with low mortality, and no major safety concerns in severe COVID-19 pneumonia"

(23 July 2020) Tocilizumab- Clinical status improved within 24 hours in 39%patients

July 25, 2020

Tocilizumab for patients with severe COVID-19: a retrospective, multi-centre study https://doi.org/10.1080/14787210.2020.1800453 This retrospective study included patients with severe COVID-19 requiring oxygen therapy who received tocilizumab in seven centers across Poland. We assessed on-treatment changes in clinical status and inflammatory markers. … Continue reading "(23 July 2020) Tocilizumab- Clinical status improved within 24 hours in 39%patients"

(17 July 2020) Tocilizumab- clinical improvement by days 7 and 14 were 44.3% (39/88) and 73.9% (65/88)

July 18, 2020

Tocilizumab for the treatment of adult patients with severe COVID‐19 pneumonia: a single‐center cohort study https://doi.org/10.1002/jmv.26308 88 consecutive patients with COVID-19 pneumonia that received at least one dose of intravenous TCZ were retrospectively analyzed. Clinical status from day 0 (first… Continue reading "(17 July 2020) Tocilizumab- clinical improvement by days 7 and 14 were 44.3% (39/88) and 73.9% (65/88)"

(15 July 2020) Tocilizumab- associated with rapid improvement in oxygenation and a faster decrease of CRP and WBC counts

July 16, 2020

Effects of Tocilizumab in Critically Ill Patients With COVID-19: A Quasi-Experimental Study https://www.medrxiv.org/content/10.1101/2020.07.13.20149328v1 In this study (Clinical trial -RBR-3zdynp), patients with COVID 19 admitted in the ICU who were treated with tocilizumab plus standard care were enrolled and compared to… Continue reading "(15 July 2020) Tocilizumab- associated with rapid improvement in oxygenation and a faster decrease of CRP and WBC counts"

(10 July 2020) Tocilizumab- early use reduced need of MV

July 11, 2020

Early use of tocilizumab in the prevention of adult respiratory failure in SARS-CoV-2 infections and the utilization of interleukin-6 levels in the management. https://doi.org/10.1002/jmv.26288 In this longitudinal observational study, 112 patients were evaluated from 2/1/2020 – 5/31/2020. TCZ was administered… Continue reading "(10 July 2020) Tocilizumab- early use reduced need of MV"

(09 July 2020) Tocilizumab- non-negligible proportion of deaths due to life-threatening hepatic reactions

July 10, 2020

Serious adverse events with tocilizumab: pharmacovigilance as an aid to prioritize monitoring in COVID-19. https://bpspubs.onlinelibrary.wiley.com/doi/epdf/10.1111/bcp.14459 To characterize serious adverse events (AEs) with tocilizumab, authors queried the worldwide FDA Adverse Event Reporting System and perform disproportionality analysis, selecting only designated medical… Continue reading "(09 July 2020) Tocilizumab- non-negligible proportion of deaths due to life-threatening hepatic reactions"

(07 July 2020) Tocilizumab- limited clinical improvement in patients

July 8, 2020

Tocilizumab in patients with severe COVID‐19: A single‐center observational analysis https://doi.org/10.1002/jmv.26191 This is a retrospective single‐center analysis of the records of patients diagnosed with COVID‐19 who received tocilizumab. Outcomes, including clinical improvement, mortality and changes in oxygen‐support at 24, 48,… Continue reading "(07 July 2020) Tocilizumab- limited clinical improvement in patients"

(30 June 2020) Tocilizumab- beneficial effects in severe-to-critically ill patients with COVID-19

July 1, 2020

This manuscript reports findings of observational research of compassionate use of tocilizumab. Tocilizumab was administered to 13 severe-to-critically ill patients with coronavirus disease 2019 (COVID-19) for compassionate use in combination with potential anti-viral agents in those who required an oxygen… Continue reading "(30 June 2020) Tocilizumab- beneficial effects in severe-to-critically ill patients with COVID-19"

(26 June 2020) Tocilizumab- 85.9% vs. 71.9% survival among tocilizumab/methylprednisolone/SOC patients vs. SOC

June 27, 2020

Tocilizumab and steroid treatment in patients with COVID-19 pneumonia https://doi.org/10.1101/2020.06.22.20133413 This observational single-center study included patients with COVID-19 pneumonia who were not intubated and received either standard of care (SOC, controls) or SOC plus early (within 3 days from hospital… Continue reading "(26 June 2020) Tocilizumab- 85.9% vs. 71.9% survival among tocilizumab/methylprednisolone/SOC patients vs. SOC"

(24 June 2020) Tocilizumab- single dose helped reduce inflammation, oxygen requirements, vasopressor support, and mortality

June 25, 2020

Compassionate Use of Tocilizumab for Treatment of SARS-CoV-2 Pneumonia https://academic.oup.com/cid/articleabstract/doi/10.1093/cid/ciaa812/5861638 In a single-center observational study of tocilizumab in hospitalized patients with SARS-CoV-2 pneumonia clinical and laboratory parameters including oxygen and vasopressor requirements, cytokine profiles, and C-reactive protein (CRP) levels pre-… Continue reading "(24 June 2020) Tocilizumab- single dose helped reduce inflammation, oxygen requirements, vasopressor support, and mortality"

Tag: Tocilizumab